All In Biotech

Drug Trial Radar · NCT02861573

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Nov 17, 2016

Primary completion

Oct 22, 2027

Study completion Jul 24, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort.

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • Pembrolizumab 200 mgBiological

    IV Q3W

  • Olaparib 400 mgDrug

    Eight 50-mg capsules PO BID

  • Docetaxel 75 mg/m^2Drug

    IV Q3W

  • Prednisone 5 mgDrug

    One 5-mg tablet PO BID

  • Enzalutamide 160 mgDrug

    Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD

  • Dexamethasone 8 mgOther

    Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W

  • Olaparib 300 mgDrug

    Two 150-mg tablets PO BID

  • Abiraterone acetate 1000 mgDrug

    Two 500-mg or four 250-mg tablets PO QD

  • LenvatinibDrug

    20 mg PO QD

  • Pembrolizumab/Vibostolimab coformulationBiological

    IV Q3W

  • CarboplatinDrug

    IV Q3W

  • EtoposideDrug

    IV on Days 1, 2 and 3 of each cycle

  • Belzutifan 120mgBiological

    PO QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)Time frame: From Baseline Measured Every 3 Weeks Until Radiographic Progression Estimated to be Approximately 2 Years
  2. Number of Participants with Adverse Events (AEs)Time frame: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
  3. Number of Participants Discontinuing Study Drug Due to AEsTime frame: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
  4. Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)Time frame: Assessed Over the Duration of the Study Which is Estimated to be Approximately 2 Years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.